<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380532</url>
  </required_header>
  <id_info>
    <org_study_id>Imm24</org_study_id>
    <nct_id>NCT04380532</nct_id>
  </id_info>
  <brief_title>Tableted COVID-19 Therapeutic Vaccine</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunitor Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and immunogenicity one-month study in healthy individuals administered once-daily pill
      of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. Healthy,
      at least 20, volunteers will be monitored for signs of adverse events. Their PBMC will be
      collected at baseline and one month later to analyze which type of immune response vaccine
      has induced.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental batch of tableted thermostable vaccine obtained from pooled plasma of COVID-19
      patients is produced. The goal of this trial is test safety and immunogenicity of
      once-per-day day administered orally to volunteers for 15 days. Baseline and post-treatment
      standard safety parameters will be compared. Blood samples from volunteers will be monitored
      and immunogenicity lab assays will be undertaken to characterize immune response.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Healthy volunteers</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on CBC as per CTCAE v4.0</measure>
    <time_frame>15 Days</time_frame>
    <description>Routine laboratory complete blood cell count at pre- and post-treatment periods by automated CBC counter Routine laboratory complete blood count Routine clinical laboratory CBC parameters at pre- and post-treatment periods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on biochemistry parameters as per CTCAE v4.0</measure>
    <time_frame>15 Days</time_frame>
    <description>Routine clinical laboratory blood biochemistry parameters at pre- and post-treatment periods by automated biochemistry analyzer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lack of adverse events as per CTCAE v4.0</measure>
    <time_frame>15 days</time_frame>
    <description>Clinical well-being assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>V-SARS recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm having at least 20 volunteers administered once-per-day pill of V-SARS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V-SARS</intervention_name>
    <description>Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month</description>
    <arm_group_label>V-SARS recipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed cases of Covid-19 (all by RT-PCR from same laboratory)

          -  Mild to severe clinical presentation (identified at the time of admission to ward by
             National Early Warning Score NEWS-2; mild 0-4; severe 5-6)

        Exclusion Criteria:

          -  Unable to take oral medication,

          -  Immunocompromised

          -  Known comorbid condition like hypertension, cardiovascular disease, diabetes mellites,
             asthma, COPD, cerebrovascular disorder, malignancy of any type, pregnancy,

          -  BMI less than 18

          -  Smoking history (more than one pack per day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldar Bourinbayar, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunitor LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Immunitor Inc</name>
      <address>
        <city>Vancouver</city>
        <state>BC - British Columbia</state>
        <zip>V6K 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aldar Bourinbayar</name>
      <address>
        <city>Ulaanbaatar</city>
        <state>BZD, 3-khoroo</state>
        <zip>13381</zip>
        <country>Mongolia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mongolia</country>
  </location_countries>
  <reference>
    <citation>Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opin Drug Deliv. 2007 Jul;4(4):323-40. Review.</citation>
    <PMID>17683247</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>coronavirus</keyword>
  <keyword>respiratory disease</keyword>
  <keyword>SARS</keyword>
  <keyword>ARDS</keyword>
  <keyword>pneumonia</keyword>
  <keyword>pandemic</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Free dissemination of published data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>when become public</ipd_time_frame>
    <ipd_access_criteria>non-confidential data</ipd_access_criteria>
    <ipd_url>http://immunitor.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

